Biogen, Eisai double down on Alzheimer’s with lecanemab filingBiogen and Eisai’s first Alzheimer’s disease drug Aduhelm is facing an uphill battle in the US market, but Share XBiogen, Eisai double down on Alzheimer’s with lecanemab filinghttps://pharmaphorum.com/news/biogen-eisai-double-down-on-alzheimers-with-lecanemab-filing/
